Fact CheckerSign in

NCT06100081Active, not recruitingPhase 2

Targeted fluorescence endoscopy for detection of the primary cancer lesion in patients with a metastasis of unknown primary tumor in the head and neck

REFLECT; Real-time targeted fluorescence endoscopy for detection of the primary cancer lesion in patients with a metastasis of unknown primary tumor in the head and neck

Source: EU CTIS (euclinicaltrials.eu) · Last updated 8 Nov 2024

Brief summary (registry, in English)

To study the feasibility of identifying primary tumors in the upper aerodigestive tract in patients with unknown primary cancer with the use of targeted fluorescence endoscopy with cetuximab-800CW as the fluorescent tracer

Status (registry)
Active, not recruiting
Phase (registry)
Phase 2
Study type
Interventional
Enrollment
35 (estimated)
First submitted
8 Oct 2024
Start date
8 Nov 2024
Lead sponsor
Universitair Medisch Centrum Groningen
NCT number
NCT06100081
EU CT number
2024-513897-23-00
EudraCT number
2018-001885-41

What you commit to

  • Study type: Interventional · Phase 2
  • Planned participants: 35
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study, not your situation.

Who cannot take part

Copied verbatim from EU CTIS (euclinicaltrials.eu) and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Concurrent uncontrolled medical conditions
  • Received an investigational drug within 30 days prior to the dose of cetuximab-800CW
  • Patients receiving Class IA (quinidine, procainamide) or Class III (dofetilide, amiodarone, sotalol) antiarrhythmic agents

Other illness

  • Medical or psychiatric conditions that compromise the patient’s ability to give informed consent
  • Inadequately controlled hypertension with or without current antihypertensive medications
  • History of allergy or infusion reactions cetuximab or other monoclonal antibody therapies

Lab values

  • History of myocardial infarction, cerebrovascular accident, uncontrolled cardiac heart failure, significant liver disease (ALT >3X upper limits of normal or increased total bilirubin) or unstable angina within 6 months prior to enrollment
  • Evidence of QT prolongation on pretreatment ECG (greater than 440 ms in males or greater than 450 ms in females)

Other

  • Life expectancy < 12 weeks
  • Karnofsky performance status < 70%
  • Pregnant or lactating women. Documentation of a negative pregnancy test must be available for women of childbearing potential. Moreover, the need to be willing to ensure that she or her partner uses effective contraception during the trial and for 6 months thereafter. Woman of childbearing potential are premenopausal women with intact reproductive organs and women less than two years after menopause

Who the study is looking for

  • Cytology and/or histology-confirmed diagnosis of squamous cell carcinoma most likely originating from the head & neck area and scheduled to undergo endoscopy of the upper aerodigestive tract as decided by the multidisciplinary head and neck tumor board of the UMCG
  • The primary tumor was not identified during standard diagnostic work-up in the outpatient clinic including physical head and neck examination, fiberoptic laryngoscopy, chest X-ray, CT and PET/CT
  • Age ≥ 18 years
  • Written informed consent

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on EU CTIS (euclinicaltrials.eu)

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Universitair Medisch Centrum Groningen
Coordinator of this site? Confirm its status
GroningenNetherlandsActive, not recruiting

This page is information, not medical advice. Discuss any trial with your doctor.